Symrise joins forces on heart products
Symrise AG and Cambridge Theranostics Ltd have entered into a strategic partnership under which Symrise will contribute up to €8 million in milestone-related payments towards the development and clinical evaluation of new health and medical food products.
The partners will share the profits on products resulting from the collaboration.
For Symrise, this step means expanding its activity into the health market. This is a logical extension of its investment in the nutraceuticals sector with the acquisition of Kaden Biochemicals GmbH in 2006. In addition, Symrise has invested €2 million in Cambridge Theranostics, a spin-off from Cambridge University, which specialises in the diagnostics and prophylaxis of cardiovascular diseases. It will use its proprietary screen to select natural products from Symrise’s extensive libraries of extracts and compounds to identify high value compounds that can afford effective protection against cardiovascular diseases.
